These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 371813)

  • 41. Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives.
    Marchal JA; Boulaiz H; Suárez I; Saniger E; Campos J; Carrillo E; Prados J; Gallo MA; Espinosa A; Aránega A
    Invest New Drugs; 2004 Nov; 22(4):379-89. PubMed ID: 15292708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I and pharmacologic study of oral ftorafur and X ray therapy in advanced gastrointestinal cancer.
    Byfield JE; Sharp TR; Hornbeck CL; Frankel SS; Floyd RA; Griffiths JC
    Int J Radiat Oncol Biol Phys; 1985 Mar; 11(3):597-602. PubMed ID: 3918971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous intravenous administration of 1-(2-tetrahydrofuryl)-5-fluorouracil [FT] by intravenous hyperalimentation (IVH)--stability of FT in IVH solution and tumor levels of 5-fluorouracil (5-FU).
    Moriya Y; Koyama Y; Hojo K; Tsunematsu R
    Jpn J Clin Oncol; 1983 Mar; 13(1):31-5. PubMed ID: 6403740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents.
    Fujii S; Kitano S; Ikenaka K; Shirasaka T
    Gan; 1979 Apr; 70(2):209-14. PubMed ID: 381088
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.
    Grau C; Overgaard J
    Cancer Chemother Pharmacol; 1992; 30(4):277-80. PubMed ID: 1643695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antitumor activity of methyl (5-fluoro-1H-2-oxo-4-pyrimidinyl beta-D-glucopyranosid)uronate against various experimental tumors.
    Arakawa M; Shimizu F; Sasagawa K; Inomata T; Shinkai K
    Gan; 1981 Apr; 72(2):220-5. PubMed ID: 6793441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytotoxicity of three novel fluoropyrimidines in cultured L1210 murine lymphocytic leukemia cells.
    Shipp AM; Holshouser MH; Ferguson PW
    Pharm Res; 1990 Dec; 7(12):1294-7. PubMed ID: 2095568
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
    Tanaka F; Fukuse T; Wada H; Fukushima M
    Curr Pharm Biotechnol; 2000 Sep; 1(2):137-64. PubMed ID: 11467334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
    Lin AJ; Benjamin RS; Rao PN; Loo TL
    J Med Chem; 1979 Sep; 22(9):1096-100. PubMed ID: 385879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of 5-fluorouracil on the cell growth and cell cycle kinetics of a mouse ascites tumor growing in vivo.
    Lewin F; Skog S; Tribukait B; Ringborg U
    Acta Oncol; 1987; 26(2):125-31. PubMed ID: 3606867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Studies in vivo and in vitro on the influence of 5-fluorouracil and n'-(2'-furanidyl)-5-fluorouracil on the walker carcinosarcoma 256 in the rat (author's transl)].
    Mattern J; Volm M; Wayss K; Weber N
    Arzneimittelforschung; 1980; 30(6):981-4. PubMed ID: 6774738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel derivatives of 5-fluorouridine and 5-fluorouracil having potent antitumor and lower immunosuppressive activities.
    Mori H; Sakamoto O; Kitaichi K; Koda A; Kita J
    Jpn J Pharmacol; 1992 Mar; 58(3):269-82. PubMed ID: 1513076
    [TBL] [Abstract][Full Text] [Related]  

  • 53. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
    Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
    Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Biochemical modulation of 5-FU by thymidine and N-phosphoacetyl-L-aspartate: the relation between 5-FU incorporation into RNA and its cytocidal effect].
    Akazawa S; Kumai R; Shimizu K; Ayusawa D; Seno T; Yoshida S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):990-5. PubMed ID: 3963863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical pharmacology of combined oral uracil and ftorafur.
    Ho DH; Covington WP; Pazdur R; Brown NS; Kuritani J; Newman RA; Raber MN; Krakoff IH
    Drug Metab Dispos; 1992; 20(6):936-40. PubMed ID: 1362949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
    Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interaction of antitumor drugs. III. Antitumor activity of tegafur in lipopolysaccharide-treated mice.
    Sasaki K; Furusawa S; Takayanagi G
    Jpn J Pharmacol; 1982 Dec; 32(6):1135-42. PubMed ID: 6819375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvant effects of calmodulin antagonists on antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil (ftorafur) and a mixture of ftorafur and uracil (UFT) in nude mice bearing human ovarian carcinomas.
    Kikuchi Y; Oomori K; Iwano I; Kizawa I; Miyauchi M; Kita T; Kuki E
    Gynecol Oncol; 1989 Nov; 35(2):172-6. PubMed ID: 2509301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine.
    Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H
    Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.